A Phase 3 interventional study of OPC-41061(Tolvaptan) in Edema, Cardiac, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 8 sites in Japan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2014-02-04.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate the efficacy and safety of 7-day repeated oral administration of OPC-41061 15 mg or placebo in congestive heart failure (CHF) patients with extracellular volume expansion despite the use of a conventional diuretic.
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0mg
Drug: OPC-41061(Tolvaptan)
15mg OPC-41061
Drug: OPC-41061(Tolvaptan)
0, 15mg of OPC-41061 per day for 7days p.o. administration
Body Weight (Amount of Change)
Change in body weight from baseline at the time of final trial drug administration
Time frame: baseline, Day 7 or at the time of final trial drug administration
Body Weight (Percent Change)
Percent change in body weight from baseline at the time of final trial drug administration
Time frame: baseline, Day 7 or at the time of final trial drug administration
| Milestone | Placebo | OPC-41061 15mg |
|---|---|---|
| Started | 57 | 53 |
| Completed | 52 | 46 |
| Not completed | 5 | 7 |
| Withdrew: Adverse event | 3 | 5 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Resolution of signs and symptoms | 0 | 2 |
Change in body weight from baseline at the time of final trial drug administration
| Kg | Placebo | OPC-41061 15mg |
|---|---|---|
| Body Weight (Amount of Change) | -0.45 ± 0.93 | -1.54 ± 1.61 |
Percent change in body weight from baseline at the time of final trial drug administration
| percentage of body weight (Kg) | Placebo | OPC-41061 15mg |
|---|---|---|
| Body Weight (Percent Change) | -0.77 ± 1.65 | -2.50 ± 2.55 |
Collected over 7 days. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 7/57 (12.3%) | 31/57 (54.4%) |
| OPC-41061 15mg | — | 2/53 (3.8%) | 28/53 (52.8%) |
| Event | Placebo | OPC-41061 15mg |
|---|---|---|
| Cardiac FailureCardiac disorders | 2/57 | 1/53 |
| Atrial FibrillationCardiac disorders | 0/57 | 1/53 |
| Renal failure chronicRenal and urinary disorders | 0/57 | 1/53 |
| Ventricular TachycardiaCardiac disorders | 1/57 | 0/53 |
| PyrexiaGeneral disorders | 1/57 | 0/53 |
| Femoral neck fractureInjury, poisoning and procedural complications | 1/57 | 0/53 |
| HyperkalaemiaMetabolism and nutrition disorders | 1/57 | 0/53 |
| Cerebral infarctionNervous system disorders | 1/57 | 0/53 |
| Event | Placebo | OPC-41061 15mg |
|---|---|---|
| Blood Urea IncreasedInvestigations | 10/57 | 5/53 |
| ConstipationGastrointestinal disorders | 3/57 | 9/53 |
| ThirstGeneral disorders | 1/57 | 9/53 |
| Blood Creatinine IncreasedInvestigations | 7/57 | 4/53 |
| PollakiuriaRenal and urinary disorders | 0/57 | 5/53 |
| Blood Potassium IncreasedInvestigations | 4/57 | 3/53 |
| NauseaGastrointestinal disorders | 0/57 | 3/53 |
| MalaiseGeneral disorders | 0/57 | 3/53 |
| Blood Uric Acid IncreasedInvestigations | 3/57 | 3/53 |
| NasopharyngitisInfections and infestations | 3/57 | 1/53 |
| Age, Categorical(Participants) | Placebo | OPC-41061 | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 19 | 12 | 31 |
| >=65 years | 38 | 41 | 79 |
| Age, Continuous(years) | Placebo | OPC-41061 | Total |
|---|---|---|---|
| Mean | 71.0 ± 10.9 | 71.3 ± 10.6 | 71.2 ± 10.7 |
| Sex: Female, Male(Participants) | Placebo | OPC-41061 | Total |
|---|---|---|---|
| Female | 18 | 18 | 36 |
| Male | 39 | 35 | 74 |
| Region of Enrollment(participants) | Placebo | OPC-41061 | Total |
|---|---|---|---|
| Japan | 57 | 53 | 110 |
The record gives a start of Apr 2007, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2014, 5 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tolvaptan
Edema, Cardiac
Otsuka Pharmaceutical Co., Ltd. →